Anaveon

Anaveon is leveraging its extensive expertise in protein engineering and immune cell targeting to advance ANV200 towards the clinic. ANV200 is a PD-1 targeting T-cell depleting antibody with potential application in several autoimmune diseases and the company is also building out an autoimmunity-focused pipeline behind it.

In parallel, Anaveon is finalising execution of its Phase I/II clinical trial for ANV600 in oncology, with Syncona continuing to believe in the anticipated clinical safety and efficacy of this programme. Anaveon will continue to seek paths to progress the molecule towards pivotal trials.

Anaveon has strengthened its leadership team with the appointments of Laetitia Pouzol as Chief Scientific Officer and Jill Jene as Chief Business Officer, to accelerate clinical development and pipeline expansion.